Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Otopalatodigital syndrome spectrum disorder is a primary bone dysplasia and encompasses a group of congenital anomalies that are characterized by skeletal dysplasia of varying clinical severity and an X linked dominant pattern of inheritance. This group include otopalatodigital syndrome type 1 and 2 (OPD1, OPD2) which are characterized in affected males by cleft palate, conductive hearing loss, craniofacial abnormalities and skeletal dysplasia; Melnick-Needles syndrome (MNS) which displays skeletal deformities in females and embryonic or perinatal lethality in most males; frontometaphyseal dysplasia (FMD); and terminal osseous dysplasia - pigmentary defects.
No HPO annotations are available for this condition.
The FLNA-related otopalatodigital (FLNA-OPD) spectrum disorders, characterized primarily by skeletal dysplasia, include the following allelic conditions: otopalatodigital syndrome type 1 (FLNA-OPD1), otopalatodigital syndrome type 2 (FLNA-OPD2), frontometaphyseal dysplasia type 1 (FLNA-FMD), Melnick-Needles syndrome (FLNA-MNS), and terminal osseous dysplasia (FLNA-TOD). To date, more than 500 individuals with an FLNA-OPD spectrum disorder have been identified [, , , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Table 4. FLNA-Related Otopalatodigital Spectrum Disorders: Frequency of Select Features
The FLNA-related otopalatodigital (FLNA-OPD) spectrum disorders, a heterogeneous group of disorders characterized primarily by a skeletal dysplasia of variable severity, include the following:
Otopalatodigital syndrome type 1 (FLNA-OPD1)
Otopalatodigital syndrome type 2 (FLNA-OPD2)
Frontometaphyseal dysplasia type 1 (FLNA-FMD)
No approved treatments are currently available for otopalatodigital syndrome spectrum disorder. The disease remains an area of unmet medical need.
No clinical practice guidelines for FLNA-related otopalatodigital (FLNA-OPD) spectrum disorders have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with an FLNA-OPD spectrum disorder, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 8. FLNA-Related Otopalatodigital Spectrum Disorders: Recommended Surveillance
No clinical trials have been registered for otopalatodigital syndrome spectrum disorder.
19 publications have been identified in PubMed for otopalatodigital syndrome spectrum disorder. Research spans Epidemiology / Natural History (39%), Case Report / Case Series (22%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 7 | 39% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 8:42 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disorder | Feature | % of Persons w/Feature |
|---|---|---|
(in males) | Digital anomalies | 100% Deafness |
(in males) | Thoracic hypoplasia | 100% Cleft palate |
(in males) | Supraorbital hyperostosis | 100% Urinary tract obstruction |
(in females) | Micrognathia | 100% Limb bowing |
(in females) | Digital fibromata | 100% Erosive changes on radiographs |
Source: GeneReviews — "FLNA-Related Otopalatodigital Spectrum Disorders"
Terminal osseous dysplasia (FLNA-TOD)
For the purposes of this GeneReview, the terms "male" and "female" are narrowly defined as the individual's biological sex at birth as it determines clinical care . No consensus clinical diagnostic criteria for FLNA-OPD spectrum disorders have been published.
FLNA-OPD spectrum disorders should be suspected in an individual with the following clinical features , radiographic feat...
Source: GeneReviews — "FLNA-Related Otopalatodigital Spectrum Disorders"
Skeletal dysplasias of interest in the differential diagnosis of FLNA-related otopalatodigital (FLNA-OPD) spectrum disorders are listed in . Table 5. Genes of Interest in the Differential Diagnosis of FLNA-Related Otopalatodigital Spectrum Disorders
Gene | Disorder | MOI | Features of Disorder |
|---|---|---|---|
Osteopathia striata w/cranial sclerosis | XL | In males: similar skeletal dysplasia to that in FLNA-OPD2; Occasionally, extraskeletal anomalies similar to those in FLNA-OPD2 | In females: striations of long bones, macrocephaly, deafness |
FLNB | Larsen syndrome (LS) atelosteogenesis type III (AOIII) (See FLNB Disorders.) | AD | Similar facial features to those in FLNA-OPD1 FLNA-FMD; Cleft palate, hearing loss, spatulate fingers toes |
MAP3K7 | MAP3K7-FMD (OMIM 617137) | AD | Very similar to FLNA-FMD |
NOTCH2 | Serpentine fibula-polycystic kidney disease (Hajdu-Cheney syndrome) (OMIM 102500) | AD | Bowing of long bones, esp fibula |
SH3PXD2B | Frank-ter Haar syndrome (OMIM 249420) | AR | Skeletal dysplasia similar to but considerably milder than FLNA-MNS |
SKI | Shprintzen-Goldberg syndrome (SGS) | AD | Skeletal dysplasia similar to FLNA-MNS FLNA-FMD (e.g., tall, square-shaped vertebrae; bowed tibiae; occasionally, fusion of upper cervical vertebrae) |
TAB2 | -FMD1 | AD | Very similar to FLNA-FMD |
Source: GeneReviews — "FLNA-Related Otopalatodigital Spectrum Disorders"
Biomarker and diagnostic research for otopalatodigital syndrome spectrum disorder has been reported in the published literature.
Table 6.
FLNA-Related Otopalatodigital Spectrum Disorders: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| • Clinical exam of extremities, joints, spine
Complete skeletal survey w/scoliosis series if indicated
| To evaluate for contractures, joint subluxations/dislocations, scoliosis
| Clinical exam for facial or skull growth asymmetry | To evaluate for craniosynostosis
Audiology eval | To evaluate for conduction sensorineural hearing loss
Clinical exam of palate referral to ENT as necessary | To evaluate for cleft palate subglottic stenosis
| Referral to pulmonologist if indicated | To evaluate for respiratory complications assoc w/thoracic hypoplasia
| Echocardiogram | To evaluate for septal defects, right ventricular outflow tract obstructive lesions, cardiomyopathy
| Dental eval | To evaluate for hypodontia, oligodontia
| Renal tract ultrasound exam | To...
Source: GeneReviews — "FLNA-Related Otopalatodigital Spectrum Disorders"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "FLNA-Related Otopalatodigital Spectrum Disorders"
View trials for otopalatodigital syndrome spectrum disorder
Evaluation |
|---|
Frequency |
|---|
Craniosynostosis | Head size shape should be monitored. | At clinical eval during infancy |
Apnea | Assess for signs/symptoms of sleep apnea. | Annually Polysomnography studies |
Deafness | Audiology eval; sensorineural component can be progressive. | Annually |
Oligohypodontia | Dental eval | Every 6-12 mos beginning w/eruption of primary dentition DXA = dual-energy x-ray absorptiometry; FLNA-FMD = FLNA-related frontometaphyseal dysplasia; FLNA-MNS = FLNA-related Melnick-Needles syndrome |
Source: GeneReviews — "FLNA-Related Otopalatodigital Spectrum Disorders"
Patient case studies
4 |
22% |
Research summaries | 3 | 17% |
Other research | 2 | 11% |
Testing and diagnosis research | 1 | 6% |
Laboratory research | 1 | 6% |
Schwarz M (2026). [PMID: 40884164](https://pubmed.ncbi.nlm.nih.gov/40884164/). *Clin Genet*. [Case Report / Case Series]
Sah U (2026). [PMID: 41675846](https://pubmed.ncbi.nlm.nih.gov/41675846/). *Ann Med Surg (Lond)*. [Case Report / Case Series]
Opper F (2026). [PMID: 41969215](https://pubmed.ncbi.nlm.nih.gov/41969215/). *BJPsych Open*. [Review / Meta-Analysis]
Srimanan W (2026). [PMID: 42017181](https://pubmed.ncbi.nlm.nih.gov/42017181/). *Clin Ophthalmol*. [Epidemiology / Natural History]
Mugada VK (2025). [PMID: 41480695](https://pubmed.ncbi.nlm.nih.gov/41480695/). *Prague Med Rep*. [Review / Meta-Analysis]
Yousaf M (2025). [PMID: 41086097](https://pubmed.ncbi.nlm.nih.gov/41086097/). *J Biomol Struct Dyn*. [Basic Science / Preclinical]
Ranjan R (2025). [PMID: 40110171](https://pubmed.ncbi.nlm.nih.gov/40110171/). *Indian J Psychol Med*. [Other]
Kumar M (2025). [PMID: 41573486](https://pubmed.ncbi.nlm.nih.gov/41573486/). *Cureus*. [Epidemiology / Natural History]
Hu X (2025). [PMID: 40521067](https://pubmed.ncbi.nlm.nih.gov/40521067/). *Postepy Dermatol Alergol*. [Diagnostic / Biomarker]
Banik S (2025). [PMID: 40750111](https://pubmed.ncbi.nlm.nih.gov/40750111/). *BMJ Case Rep*. [Case Report / Case Series]